PAMS
NPCE icon

Pictet Asset Management (Switzerland)’s Neuropace NPCE Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-560,444
Closed -$5.65M – 1723
2021
Q4 		$5.65M Sell
560,444
-9,431
-2% -$122K 0.01% 808
2021
Q3 		$9.03M Buy
+569,875
New +$12M 0.01% 687

Other funds holding NPCE

KL
KCK Ltd Hamilton, Bermuda $15.1M AUM 30.14% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RCM
Revelation Capital Management Sausalito, California $67.4M AUM

Pictet Asset Management (Switzerland)'s NPCE Position: Q1 2022 in Review

Pictet Asset Management (Switzerland) sold out of Neuropace (NPCE) in Q1 2022, closing a stake of 560,444 shares — an estimated $5.65M sold.

Pictet Asset Management (Switzerland) first reported a position in NPCE in Q3 2021 and held it in 2 quarters. The position peaked at $9.03M in Q3 2021. 40 funds tracked by Wall St. Rank hold NPCE as of Q1 2022.

  • Pictet Asset Management (Switzerland) reported no remaining Neuropace position as of Q1 2022 after selling out during the quarter.
  • Pictet Asset Management (Switzerland) sold 560,444 Neuropace shares in Q1 2022, an estimated $5.65M.
  • Pictet Asset Management (Switzerland) first reported a position in Neuropace in Q3 2021 and held it in 2 quarters.
  • Pictet Asset Management (Switzerland)'s Neuropace position peaked at $9.03M in Q3 2021.
  • 40 funds tracked by Wall St. Rank held Neuropace as of Q1 2022.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q1 2022, filed 13 May 2022.